Document is current
Any future updates will be listed below
-
Authors
Fumagalli, Valeria https://orcid.org/0000-0003-2583-2498
Ravà, Micol https://orcid.org/0000-0001-7606-8368
Marotta, Davide https://orcid.org/0000-0003-1918-050X
Di Lucia, Pietro
Bono, Elisa B.
Giustini, Leonardo
De Leo, Federica
Casalgrandi, Maura
Monteleone, Emanuele https://orcid.org/0000-0001-7440-900X
Mouro, Violette
Malpighi, Chiara
Perucchini, Chiara
Grillo, Marta
De Palma, Sara
Donnici, Lorena https://orcid.org/0000-0002-9153-9102
Marchese, Silvia https://orcid.org/0000-0003-3822-7174
Conti, Matteo
Muramatsu, Hiromi
Perlman, Stanley https://orcid.org/0000-0003-4213-2354
Pardi, Norbert https://orcid.org/0000-0003-1008-6242
Kuka, Mirela https://orcid.org/0000-0001-9418-1559
De Francesco, Raffaele https://orcid.org/0000-0001-8754-5123
Bianchi, Marco E. https://orcid.org/0000-0002-5329-6445
Guidotti, Luca G. https://orcid.org/0000-0002-0205-2678
Iannacone, Matteo https://orcid.org/0000-0002-9370-2671
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (19891, 22737)
Ministero dell'Istruzione, dell'Università e della Ricerca (PE00000007 (INF-ACT), PRIN 2022FMESXL, PE00000007 (INF-ACT))
Ministero dell'Istruzione, dell'Università e della Ricerca
- License Information
-
More Information
Article History
Received: 27 September 2023
Accepted: 13 February 2024
First Online: 14 March 2024
Competing interests
: M.I. participated in advisory boards/consultantship for Asher Biotherapeutics, GentiBio, Clexio Biosciences, Sybilla Biotech, BlueJay Therapeutics, Bristol Myers Squibb, Aligos Therapeutics and receives funding from Asher Biotherapeutics and VIR Biotechnology. N.P. is named on patents describing the use of nucleoside-modified mRNA in LNPs as a vaccine platform. He has disclosed those interests fully to the University of Pennsylvania and has in place an approved plan for managing any potential conflicts arising from the licensing of those patents. He served on the mRNA strategic advisory board of Sanofi Pasteur in 2022 and is a member of the Scientific Advisory Board of AldexChem. The other authors declare no competing interests.
